geographic atrophy
Jump to navigation
Jump to search
Etiology
- macular degeneration
- advanced dry form of age-related macular degeneration
Epidemiology
- affects > 1 million people in the U.S. & 5 million people worldwide
Complications
- major cause of adult blindness
Management
- pegcetacoplan (Syfovre) injection administered every 25-60 days (FDA-approved)
- maximum benefit between 18-24 months after initiating treatment.
- avacincaptad pegol (Izeray)
- photovoltaic retina implant microarray (PRIMA) system
More general terms
References
- ↑ Marcus A FDA OKs First Drug for Geographic Atrophy, a Major Cause of Adult Blindness. Medscape. February 17, 2023 https://www.medscape.com/viewarticle/988460
- ↑ 2.0 2.1 Holz FG, Le Mer Y, Muqit MMK et al Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. NEJM 2025 October 20 Not yet indexed in PubMed https://www.nejm.org/doi/full/10.1056/NEJMoa2501396
Drew L People with blindness can read again after retinal implant. Nature News. 2025. Oct 20. https://www.nature.com/articles/d41586-025-03420-x